Johnson & Johnson (JNJ)
NYSE: JNJHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
JNJ stock chart
Technical analysisKey statistics
All statistics- Market cap
- $651.11B
- P/E (TTM)
- 41.04
- Forward P/E
- 23.29
- EPS (TTM)
- $6.59
- Dividend yield
- 1.95% ($5.28)
- Ex-dividend date
- Aug 25, 2026
- 52-week range
- 199.91 – 290.25
- Day range
- 269.47 – 272.48
- Volume / Avg
- 11.92M / 7.29M
- Beta
- —
- Shares outstanding
- 2.41B
- Next earnings
- Jan 26, 2027
52-week range
JNJ stock today
Shares of Johnson & Johnson (JNJ) finished higher on Nov 20 at $270.47, a gain of 1.25% or $3.33 per share, versus the S&P 500's 3.70% decline. At this level, JNJ sits in the middle of its 52-week range of $199.91 to $290.25: 6.8% below the high, set on Nov 16, 2026 and 35.3% above the low. JNJ is up 30.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 32.6%.
At 41.0x trailing earnings, Johnson & Johnson trades above the peer-group median of 35.8x. Its forward P/E of 23.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Johnson & Johnson's next earnings report is expected on Jan 26, 2027. Johnson & Johnson pays an annual dividend of $5.28 per share, a 1.95% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Johnson & Johnson
Company profileJohnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Joaquin Duato
- Headquarters
- New Brunswick, NJ
- Employees
- 138,200
- Website
- jnj.com
Financial highlights
Full financialsIn fiscal 2025, Johnson & Johnson generated $94.19 billion in revenue, up 6.0% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $26.80 billion (+90.6% year over year), for a net margin of 28.5% versus a median of 22.4% in the prior 5 years. Gross margin was 67.9% (down from 69.1%).
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B |
| Growth | +6.05% | +4.30% | +6.46% | +1.59% | -4.65% |
| Net income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B |
| EPS (diluted) | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 |
Analyst forecast
ForecastConsensus (23 analysts)
buy
Avg. price target
$279.41+3.31%
- Strong buy 5
- Buy 11
- Hold 6
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Jan 26, 2027
- Last reported (Sep/2026)
- Oct 13, 2026
- EPS actual vs est.
- $2.59 vs $2.53
- Surprise
- +2.37%
Dividends
Dividend history- Annual dividend
- $5.28
- Dividend yield
- 1.95%
- Last payment
- $1.34
- Ex-dividend date
- Aug 25, 2026
JNJ news
All JNJ news- Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?Nasdaq
- Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?NasdaqJNJ, PFE, LEN.B
- Johnson & Johnson's TREMFYA Meets Key Endpoints In First Dedicated Phase 4 Axial PsA StudyNasdaq
- Weekly Buzz: SNY, REGN Score Approvals; MIST Cuts Costs; ABBV, LLY, JNJ Strike DealsNasdaqABBV, BIIB, BMY, ENLV
- HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock DownNasdaqMRK, HALO, JNJ, ARGX
- Dividend Roundup: Nvidia, Disney, Merck, Johnson & Johnson and moreSeeking AlphaJNJ, NVDA
- Johnson & Johnson's TREMFYA Reduces MRI-Assessed Inflammation In Axial Psoriatic ArthritisNasdaq
- Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffnessPR Newswire
Johnson & Johnson peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ABBVAbbVie Inc. | 286.20 | +0.94% | $505.89B | vs JNJ |
| MRKMerck & Company Inc. | 133.72 | +0.69% | $329.65B | vs JNJ |
| NVSNovartis AG | 150.47 | -0.50% | $284.18B | vs JNJ |
| AZNAstraZeneca PLC | 174.35 | -0.60% | $270.40B | vs JNJ |
| ABTAbbott Laboratories | 103.00 | -0.84% | $178.39B | vs JNJ |
| NVONovo Nordisk A/S | 37.82 | -2.70% | $166.69B | vs JNJ |
| PFEPfizer Inc. | 27.40 | -0.51% | $156.18B | vs JNJ |
| VRTXVertex Pharmaceuticals Incorporated | 515.02 | -1.08% | $130.58B | vs JNJ |
Indexes, lists and sector
Index membership
Appears in lists
Johnson & Johnson stock FAQ
What is Johnson & Johnson's stock price today?
JNJ last traded at $270.47 as of Nov 20, 4:00 PM EST, up 1.25% on the day. Prices are delayed at least 15 minutes.
Does Johnson & Johnson pay a dividend?
Yes. Johnson & Johnson pays $5.28 per share annually, a 1.95% yield. The most recent dividend of $1.34 had an ex-dividend date of Aug 25, 2026.
When is Johnson & Johnson's next earnings date?
Johnson & Johnson is expected to report earnings on Tuesday, January 26, 2027.
What is JNJ's P/E ratio?
JNJ trades at a trailing P/E ratio of 41.04 and a forward P/E of 23.29, compared with a median of 35.8 for its closest peers.
Is Johnson & Johnson in the S&P 500?
Yes. Johnson & Johnson (JNJ) is a constituent of the S&P 500 index.
Who is Johnson & Johnson's CEO?
Mr. Joaquin Duato is the chief executive officer of Johnson & Johnson, which has about 138,200 employees.
Has JNJ ever split its stock?
Yes. The most recent JNJ stock split was a 2-for-1 split on Jun 13, 2001, one of 6 splits on record.